Connect for Cancer Prevention Study
The Connect for Cancer Prevention Study is an observational study looking at how our lifestyles, genes, and health history might affect cancer risk. Researchers hope to better understand what causes cancer and find new ways to prevent it. This study doesn't test a specific drug or intervention. Instead, it collects information and biological samples over time to see how different factors relate to cancer. The study aims to enroll 200,000 adults, aged 30 to 70, who receive healthcare from one of the partner health systems and have never had cancer. Success for this study means understanding cancer incidence (how often new cancers occur), progression (how cancers change over time), and mortality (death from cancer) starting from year one and continuing.
- Study design
- This is an observational study planning to enroll 200,000 participants. It will follow participants over time without assigning specific treatments.
- What's involved
- Participants will be asked to provide repeated information about their exposures and biological specimens. The study will follow participants for cancer and other health outcomes.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for cancer incidence, progression, and mortality starting at year one and onward.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Connect for Cancer Prevention Study (Connect)
At a glance
Conditions
Where it's being run
10 sites across 10 statesStudy leadership
- Nicolas A Wentzensen, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- cancer incidence, progression, and mortalityyear one and onward
cancer incidence, progression, and mortality outcomes could include, but are not limited to:early biological effects (e.g., inflammation or metabolomic markers) related to cancer, intermediate biomarkers, cancer precursors, cancer risk factors, cancer incidence, cause of death, cancer survival, risk of second cancers and survivorship